Try our beta test site

Identify Training Strategies for Progressing Exoskeleton Users Towards Everyday Functional Ambulation

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
U.S. Department of Education
Information provided by (Responsible Party):
Arun Jayaraman, Rehabilitation Institute of Chicago
ClinicalTrials.gov Identifier:
NCT02104622
First received: February 26, 2014
Last updated: February 12, 2016
Last verified: February 2016
  Purpose
Many people with spinal cord injury are no longer able to walk and must use wheelchairs for mobility. These individuals experience greater rates of depression and lower quality of life. Many of these individuals express a strong desire to walk again, and report many psychosocial benefits to being eye to eye with peers in social interactions. Additionally, wheelchairs allow only limited community access, creating an additional obstacle to seeking out meaningful social roles in the community. Currently, there is new technology called robotic exoskeletons that would allow people with spinal cord injury to walk. These robotic exoskeletons also allow for curb, ramp, and stair negotiation, which are critical to community access. Current research has examined training with robotic exoskeletons indoors over level surfaces in clinical settings. This study will examine the potential for everyday use, including ramps, stairs, curbs and indoor and outdoor use.

Condition Intervention Phase
Spinal Cord Injury
Device: ReWalk Rehabilitation 2.0
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Identify Training Strategies for Progressing Exoskeleton Users Towards Everyday Functional Ambulation

Resource links provided by NLM:


Further study details as provided by Rehabilitation Institute of Chicago:

Primary Outcome Measures:
  • Change in 6 Minute Walk Test from baseline in distance, RPE and oxygen uptake [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]
    The goal is to cover as much ground as possible over 6 minutes, the distance is measured with a measuring wheel. The instructions are "Walk continuously if possible, but do not be concerned if you need to slow down or stop to rest." At the end of 6 minutes the participant is asked to rate their exertion level on a Borg Scale of 6 - 20 points. The VO2 MAX data is collected during the test every 10 seconds

  • Change in 10 meter walk test from baseline in gait speed [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]
    Measure the time in second for and individual to walk 10 meters. The test is Performed using a "flying start," patient walks 10 meters (33 ft) and the time is measured when the leading foot crosses the start line and the finish line. The instructions are: " Please walk this distance as fast as you safely can when I say go."

  • Time and assistive level to negotiate stairs, ramps, curbs, and turning. [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]
  • Distance able to reach while standing and sitting [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]

Secondary Outcome Measures:
  • Patient perception of Quality of Life [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]
  • The Patient Health Questionnaire [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]
    PHQ-9 is a 9-item self-report questionnaire designed to diagnose both the presence of depressive symptoms as well as to characterize the severity of depression. A single question rates how difficult problems have made it to do work, take care of things at home or get along with other people using a 4 level scale (not difficult at all to extremely difficult).

  • The Psychosocial Impact of Assistive Devices Scale [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]
    The PIADS is a 26-item, self-report questionnaire designed to assess the effects of an assistive device on functional independence, well-being, and quality of life. The PIADS can be used to assess the impact of any assistive device (AD), prosthesis or medical procedure. It can be used to evaluate the impact of ADs over time and to match the devices with consumers. With its excellent psychometric properties, the PIADS fills a missing link in the assessment of ADs as well as in the examination of their acceptance and abandonment.

  • Activities-specific Balance Confidence Scale [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]
  • Self reported Spinal Cord Independence Measure in activities of daily living [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]
  • Pain measure by the Visual Analogue Scale [ Time Frame: Session 1 (pre test, initial visit) and Session 20 (post test, between 6-8 weeks) ]

Estimated Enrollment: 20
Study Start Date: February 2014
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ReWalk training Device: ReWalk Rehabilitation 2.0

  Eligibility

Ages Eligible for Study:   12 Years to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • SCI level C6-8, T1-T12; L1-L5 incomplete or complete
  • Be able to physically fit into the exoskeleton device;
  • Be able to tolerate upright standing for a minimum of 30 minutes;
  • Have sufficient upper body strength to use forearm crutches in standing and during ambulation (including full triceps strength and good hand function);
  • Have hip, knee, and ankle range of motion within normal functional limits of walking;
  • Have the ability to follow directions and demonstrate learning capacity;
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

  • Cervical level SCI above C6
  • History of severe osteoporosis;
  • Weight above 220 pounds;
  • Femur length above 47 cm or below 36 cm
  • Joint contractures at the hip, knee, or ankle that limit normal range of motion (ROM) during ambulation;
  • Cognitive and/or communication disability (e.g. due to brain injury);
  • History of significant problems with skin break down or current skin break down;
  • Any medical issue that precludes full weight bearing and ambulation (e.g. orthopedic injuries, pain, severe spasticity);
  • Pregnancy;
  • Cardiovascular conditions such as history of heart attack, high blood pressure, pacemaker, arrhythmia, heart failure, or stroke.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02104622

Locations
United States, Illinois
Rehabilitation Institute of Chicago
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Rehabilitation Institute of Chicago
U.S. Department of Education
Investigators
Principal Investigator: Arun Jayaraman, PT, PhD Rehabilitation Institute of Chicago
  More Information

Responsible Party: Arun Jayaraman, Research Scientist, Rehabilitation Institute of Chicago
ClinicalTrials.gov Identifier: NCT02104622     History of Changes
Other Study ID Numbers: 89259
Study First Received: February 26, 2014
Last Updated: February 12, 2016

Keywords provided by Rehabilitation Institute of Chicago:
spinal cord injury
exoskeleton
ambulation
walking
robotics

Additional relevant MeSH terms:
Spinal Cord Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries

ClinicalTrials.gov processed this record on March 22, 2017